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Langat virus (LGT), a tick-borne flavivirus, is naturally attenuated for humans but it is very virulent in SCID mice. In contrast,
viable recombinant chimeras of LGT (preM and E genes) and dengue type 4 virus (all other sequences) recovered in mosquito
cell culture were completely attenuated in SCID mice but still capable of providing protection against LGT. To develop the
chimeras into vaccine candidates, we adapted them to replicate efficiently in simian Vero cells, a satisfactory substrate for
human vaccines. The adapted chimeras remained completely attenuated for SCID mice and, significantly, provided protection
in immunocompetent mice against tick-borne encephalitis virus, the most virulent of the tick-borne flaviviruses. © 2000
Academic PressThe tick-borne virus complex of the Flaviviridae family
includes tick-borne encephalitis (TBE), Kyasanur forest
disease, Langat (LGT), Louping ill, Negishi, Omsk hem-
orrhagic fever, and Powassan viruses (for a review, see
(1)). This group of viruses is endemic throughout most of
the northern hemisphere and except for Langat virus
causes human disease of varying severity. Viruses of this
flavivirus complex are maintained in nature by a cycle
involving ticks and wild rodent hosts. Based on vector
transmissibility, serological analysis, and sequence anal-
ysis of isolates from Europe and Asia, TBE virus (TBEV)
has been subdivided into two closely related subtypes, a
European subtype (also referred to as Central European
encephalitis) and a Far Eastern subtype (formerly called
Russian spring–summer encephalitis) (1–3). Disease
caused by TBEV is more severe in the Far East than in
European countries, with a case fatality rate of up to 30%
as well as neurologic sequelae, which occur in 30–60%
of survivors. Currently, a vaccine produced by formalin
inactivation of TBEV is available, but multiple inocula-
tions are required to achieve a satisfactory level of re-
sistance and the breadth of its protective effect has been
questioned. For these reasons, we were interested in
developing an improved vaccine against TBEV and other
members of the tick-borne flavivirus complex.
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26Recently, we developed a new approach to immuno-
prophylaxis, which involved the construction of recombi-
nant chimeric flaviviruses that were devoid of detectable
neuroinvasiveness (4–6). These chimeric viruses con-
tained the genes for structural proteins preM and E of
TBEV or Langat virus, which were substituted for the
corresponding genes of dengue type 4 virus (DEN4). This
substitution was achieved using full-length infectious
DEN4 cDNA (7). The resulting TBEV/DEN4 or LGT/DEN4
chimera exhibited a reduction in neurovirulence for mice,
as tested by intracerebral inoculation. However, more
impressive was the effect of chimerization on neuroinva-
siveness, a property that reflects the capacity of a virus
to replicate at a peripheral site and then spread to the
central nervous system, where it causes encephalitis.
Chimerization of TBEV or LGT with DEN4 completely
ablated detectable neuroinvasiveness when assayed by
the most sensitive indicator system, the SCID mouse. For
example, peripheral inoculation of 107 plaque-forming
units (PFU) of either chimera failed to produce enceph-
alitis in SCID mice (6, 8). Also, in a previous study, a
TBEV/DEN4 chimera that lacked neuroinvasiveness in
SCID mice induced a protective immune response in
normal mice that conferred complete resistance to chal-
lenge by homotypic, highly virulent TBEV (4). More re-
cently we observed that the preM and E proteins of LGT
in the LGT/DEN4 chimera provided significant protection
when previously immunized mice were challenged intra-
peritoneally (ip) with wild-type LGT strain TP21 (6).
The tick-borne flaviviruses share envelope glycopro-
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27RAPID COMMUNICATIONtein epitopes that provide cross-resistance among vi-
ruses of this antigenically related group (1, 9, 10). This
conservation of protective neutralization epitopes on the
envelope glycoprotein includes Langat virus, a virus that
is highly, but not totally, attenuated for humans. More
than two decades ago this virus was evaluated as a
candidate vaccine in over 600,000 persons in the former
Soviet Union (11). At first the virus appeared to be com-
pletely attenuated, but the clinical trial was terminated
when it became apparent that central nervous system
signs developed at a rate of one such adverse reaction
per 18,570 vaccines. Notably, the experimental vaccine
virus induced durable immunity to TBE disease in en-
demic areas. In support of this finding, other studies
indicated that immunization of experimental animals and
human volunteers with Langat TP21 or E5 induced a high
level of serum neutralizing antibodies against virulent
members of the tick-borne flavivirus complex such as
TBEV, Kyasanur forest disease virus of India, and Powas-
san virus of the northern U.S.A. and Canada (9, 11, 12).
These serological responses provided direct evidence
for conservation of protective epitopes among tick-borne
flaviviruses, including the naturally attenuated Langat
virus.
Although Langat virus (strain TP21) and its more at-
tenuated chick embryo cell culture passage derivative,
strain E5, were significantly attenuated for mice and
monkeys, these viruses exhibited some neurovirulence
(after intracerebral inoculation) and neuroinvasiveness
(after peripheral inoculation) in mice, albeit less than that
exhibited by TBEV (6, 13, 14). However, this residual
reduced level of virulence of both strain TP21 and strain
E5 was completely ablated by constructing viable chime-
ras with DEN4, in which the preM and E genes of TP21
or E5 were substituted for the corresponding genes of
DEN4 (6).
Ablation of the residual neuroinvasiveness of the LGT
strains TP21 and E5 suggested that one of these chime-
ras might prove to be useful as a live attenuated virus
vaccine for prevention of disease caused by tick-borne
flaviviruses. The present study addresses issues of the
immunogenicity of the chimeric LGT/DEN4 vaccine can-
didates in mice and the ability of the chimeras to induce
resistance to challenge with highly virulent TBEV.
Characterization of Vero Cell-Passaged LGT/DEN4
Chimeras. Two viable chimeric viruses that contained
preM and E genes of wild-type LGT strain TP21 or its
more attenuated derivative, LGT strain E5, with remain-
ing sequences derived from DEN4 were recovered after
transfection of mosquito C6/36 cells with full-length RNA
transcripts of the full-length cDNA chimeric genome;
however, infectious virus could not be recovered follow-
ing transfection of simian cells (6). It should be noted that
the former cells are considered to be unsuitable for
preparation of human vaccines. Initially, both TP21/DEN4
a
sand E5/DEN4 chimeras recovered in mosquito cells
were significantly reduced in efficiency of viral replica-
tion and plaque formation in simian cells compared with
parental TP21 or E5 virus as well as parental DEN4.
However, it was possible to adapt the chimeric viruses to
grow efficiently in certified Vero cells (W.H.O. Seed, 143
passage; Novavax, Inc., Rockville, MD) suitable for use in
production of human vaccines. This was accomplished
by inoculating Vero cells with TP21/DEN4 or E5/DEN4
virus at a multiplicity of infection of 1 or 5 and harvesting
2- to 4.5-mm virus plaques that developed after 10 days
of incubation at 37°C. These plaque isolates were then
subjected to four plaque to plaque passages in Vero
cells in a successful attempt to select for virus that grew
to higher titer and produced plaques more efficiently.
Seed stock of Vero cell culture-derived TP21/DEN4 or
E5/DEN4 virus was prepared by passage of fourth-
plaque-passage virus in Vero cells.
The Vero cell-adapted vaccine candidates (vac) TP21/
DEN4(vac) and E5/DEN4(vac) were then compared with
each other and with their parental viruses with respect to
neuroinvasiveness in mice, plaque morphology, and
maximum yield in simian and mosquito cells. The titers
attained by the Vero cell-adapted TP21/DEN4(vac) and
5/DEN4(vac) chimeras were 4.6 3 106 and 3 3 106
PFU/ml in Vero cells and 1 3 106 and 3 3 106 PFU/ml in
osquito C6/36 cells, respectively, indicating that parity
ad been achieved.
The increased cytopathic effect of the Vero cell-
dapted chimeras in Vero cells suggested that host
ange mutations in the virus genome were selected dur-
ng adaptation and propagation of these viruses in sim-
an cells. For this reason a partial sequence of each
himeric virus genome was determined by RT–PCR anal-
sis of RNA extracted from purified virions to verify their
himeric structure and identify mutations that might play
role in Vero cell adaptation. Primer pairs (oligo 239 and
ligo 442; see (5)) that amplify the DEN4 genome from
ucleotide 18 to nucleotide 2832 were used to generate
CR products. The nucleotide sequence of the 59 non-
oding region, the structural protein genes, and the non-
tructural protein NS1 gene of each Vero cell culture-
erived chimeric genome, including the C/preM and
/NS1 junctions, was determined and compared with the
ublished sequence of the corresponding mosquito cell
ulture-derived chimeric virus genome (Table 1) (6). Only
hree amino acid differences were identified and these
ere located in the E protein sequence of the TP21/
EN4(vac) chimera that had been passaged five times in
ero cells following recovery in mosquito C6/36 cells. In
similar comparison, there were only eight nucleotide
ifferences in the sequence of the Vero cell-adapted
5/DEN4(vac) chimera, of which six produced an amino
cid substitution, and these were located in the preM
nd envelope structural protein (E). The same amino acid
ubstitutions in E at position 296 (Lys 3 Gln) and posi-
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28 RAPID COMMUNICATIONtion 310 (Thr3 Ala) were documented in the two chime-
ras. These shared mutations may play a role in alteration
of cell tropism.
The change at nucleotide position 1437 of the E5/
DEN4(vac) genome results in an amino acid substitution
of Ile for Thr151 in a potential glycosylation site of the E
rotein. Immunoprecipitation of viral E proteins from ly-
ates of Vero cells infected with either a parental LGT
irus or its chimeric virus indicated a difference in gel
igration of the E protein of parental E5 virus and its
himeric E5/DEN4(vac) virus (data not shown). The E
rotein of the E5/DEN4 chimera migrated slightly faster
han the E protein of the E5 virus. This probably reflects
oss of one of the three potential N-linked glycosylation
T
Mutations Acquired When TP21/DEN4 and E5/DEN
to Grow Efficient
Region of
viral genome
Nucleotide
position
TP21/DEN4 virus grow
C6/36 cells Ve
C 212b
Pre-M 643
870
E 1437
1856 A
1898 A
1973
2371b G
2403b
a Virus recovered from cDNA in mosquito C6/36 cells and then pass
b Nucleotide number for DEN4 genome.
c Results in loss of potential glycosylation site.
T
Neuroinvasiveness of Vero Cell-Grown
Mice
Vero cell-grown LGT strains and LGT/DEN
Virus
Amount of virus
inoculated ip as
determined in
Vero cells (PFU)
% mo
(No. dead
Swiss TP21/DEN4(vac) 5 3 105 0 (
E5/DEN4(vac) 5 3 105 0 (
TP21 1 3 105 100 (
E5 1 3 105 0 (
SCID TP21/DEN4(vac) 5 3 105 0 (
E5/DEN4(vac) 5 3 105 0 (
TP21 1 3 102 100 (
E5 1 3 102 100 (
a Ip LD50 (PFU) determination based on titration in mosquito cells (R
presented for purpose of comparison.
b Five surviving mice were challenged ip on day 50 with 102 PFU of
of the five remaining survivors were collected on day 50 and tested for viral g
of Vero cell cultures that were analyzed by immunofluorescence for viral antiites in the E protein. In contrast, gel mobilities of the E
lycoprotein of TP21 and its chimeric TP21/DEN4(vac)
irus did not differ.
Mouse Neuroinvasiveness. In a previous study, LGT
P21 inoculated ip was only moderately attenuated for
mmunocompetent mice (6). In contrast, LGT E5 (an egg-
assage derivative of TP21), TP21/DEN4, and E5/DEN4
ere completely attenuated when normal mice were
noculated by the ip route. However, the parental LGT
iruses inoculated ip exhibited a very high level of viru-
ence for SCID mice; the ip LD50 was 4 3 10
23 PFU for
P21 and 6 3 1022 PFU for E5 (Table 2) (6). Significantly,
his high level of virulence of the LGT strains for SCID
eras Recovered in Mosquito Cells Were Adapted
imian Vero Cells
E5/DEN4 virus grown in
Amino acid
changea C6/36 cells Vero cellsa
U C
G A
U C Phe151 3 Ser
C U Thr151 3 Ile
c
A C Lys296 3 Gln
A G Thr310 3 Ala
A U Thr335 3 Ser
Cys480 3 Phe
G A Gly491 3 Ser
ive times in simian Vero cells.
EN4 Chimeras Used for Immunization
ras tested
Previously determined
neuroinvasiveness (LD50) of mosquito
cell-grown LGT/DEN4 chimerasated)
Estimated LD50
(PFU)
.5 3 105 .105
.5 3 105 .105
,105 5 3 103
.105 .107
.5 3 105 .107
.5 3 105 .107
,102 4 3 1023
,102 6 3 1022
LGT strains TP21 and E5 were titered in Vero cells. Data from Ref. 6
irus. All mice died 10 to 13 days postchallenge. Brain, liver, and bloodABLE 1
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C
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LGT/D
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rtality
/no. tes
0/10)
0/5)
10/10)
0/5)
0/10)b
0/10)b
10/10)
10/10)
ef. 6).
TP21 v
enome by direct RT–PCR analysis and for viable virus by inoculation
gens 7 days later.
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29RAPID COMMUNICATIONmice was totally ablated when TP21 or E5 was used to
construct a viable LGT/DEN4 chimera. In a previous
study, the ip LD50 in SCID mice for the two chimeras
“rescued” and propagated in mosquito cells was .107
PFU (6). In the present study a similar analysis was
performed for the Vero cell-adapted chimeras to deter-
mine if this level of attenuation for SCID mice had been
retained after the chimeras were adapted to certified
Vero cells that are qualified for use in the manufacture of
a human vaccine.
Three-week-old Swiss mice and immunodeficient
(SCID) mice (C.B.-17 ICR/scid/scid; Taconic Farms, Ger-
mantown, NY) were used to assess virulence (Table 2).
At a dose of 105 PFU delivered ip, parental TP21 caused
00% mortality in Swiss mice, whereas LGT E5, the
P21/DEN4(vac) chimera, and the E5/DEN4(vac) chimera
ailed to cause fatal disease when inoculated ip at a
ose of 105 or 5 3 105 PFU. In addition, complete atten-
ation of both chimeric viruses was observed when
CID mice were inoculated ip. Although TP21 and E5
iruses produced 100% mortality when SCID mice were
noculated ip with 102 PFU, neither mortality nor illness
as observed when SCID mice were inoculated ip with
3 105 PFU of either LGT/DEN4 chimera. This indicates
hat Vero cell-adapted viruses, like their mosquito cell-
rown parents, were significantly attenuated for mice
nder these conditions.
To determine if SCID mice that survived 7 weeks after
p inoculation with either LGT/DEN4 chimera were sus-
eptible to challenge with parental TP21, surviving mice
ere inoculated ip with 102 PFU of TP21. As expected, all
of these mice died between 10 and 13 days postinocu-
lation. We were also unable to recover infectious virus or
detect viral RNA by PCR 50 days after ip inoculation of
either highly attenuated chimera. Thus, we were unable
to detect evidence of persistent infection.
Protection against Challenge with Virulent TBEV. The
studies involving TBEV challenge were carried out in a
biosafety level 4 laboratory at the Chumakov’s Institute of
Poliomyelitis and Viral Encephalitides, Moscow region,
Russia, or at the U.S. Army Medical Research Institute of
Infectious Diseases (Fort Detrick, MD) in accordance
with procedures described in the Guide for the Care and
Use of Laboratory Animals (18).
Protection Induced by Immunization with a 600 PFU
Dose of the TP21/DEN4 Chimera (Table 3). In the first
experiment, 6-week-old inbred CBA mice (14–20 g) in
groups of 9 or 10 were inoculated ip with 600 PFU of
TP21/DEN4(vac) once or twice with an interval of 29 days
between inoculations. Immunized as well as nonimmu-
nized (control) mice were challenged ip on day 26 or 55
with 320 PFU (32LD50) of the highly neuroinvasive TBEV
strain Absettarov, a European subtype virus (3). The ip
LD50 of this strain for 14- to 20-g CBA mice was estimated
o be 10 PFU. Mice immunized with a single 600 PFU
f
nose of the chimeric vaccine were only partially pro-
ected (60%) against 32LD50 of the virulent TBEV strain,
hereas two inoculations of a 600 PFU dose of the
himera conferred complete protection against heterol-
gous challenge with TBEV. In contrast, all 19 control
BA mice developed clinical signs consistent with lethal
BEV infection and died when challenged with TBEV.
During the second experiment, a similar protocol was
sed to study the TP21/DEN4 chimera in BALB/c mice.
our-week-old BALB/c female mice (10–14 g) in groups of
or 10 were inoculated ip with 600 PFU of TP21/
EN4(vac) chimera one or more times with an interval of
6 to 66 days between inoculations (Table 3). Mice were
hallenged ip at the indicated time(s) with a dose of
20LD50 of TBEV strain Absettarov, for which the ip LD50
for 10- to 14-g BALB/c mice was estimated to be 1 PFU.
In this experiment as well as the first experiment, non-
immunized mice that served as controls were the same
age as immunized mice to eliminate an effect of age-
related resistance of mice to TBEV. All 40 nonimmunized
mice challenged with TBEV died with clinical signs of
lethal TBEV infection. BALB/c mice inoculated with a
single dose of the TP21/DEN4(vac) chimera were poorly
protected against TBEV compared to CBA mice. How-
ever, protective efficacy increased when two or three
doses of the chimeric vaccine strain were given. Com-
plete protection to TBEV challenge was achieved when
the vaccine candidate was inoculated four times over a
period of 127 days.
Protection Induced by Inoculation with a 105 PFU Dose
of a Candidate LGT/DEN4 Vaccine (Table 4). Three-
week-old outbred Swiss female mice (7–9 g) were inoc-
ulated by the ip route with (i) 102 PFU of LGT TP21 virus,
LGT E5 virus, or a cDNA-derived LGT TP21 virus (desig-
nated 656) (8) or (ii) 105 PFU of TP21/DEN4(vac), E5/
DEN4(vac), or DEN4. When the candidate vaccine was
administered twice, the second inoculation was given
after an interval of 22 days. Eighteen days after the
second immunization, all of the mice were bled to mea-
sure the level of serum neutralizing antibodies against
LGT TP21 virus, and 6 days later mice were challenged
ip with a 100LD50 of the highly virulent strain Sofjin of
TBEV, Far Eastern subtype (2). The 50% lethal dose of the
Sofjin strain for 8-week-old mice was previously deter-
mined to be 0.5 PFU (10).
Previous studies in mice demonstrated a tight corre-
lation between the level of serum neutralizing antibodies
to tick-borne flavivirus induced by immunization and the
resistance to challenge with homologous virus or other
closely related members of this group (1, 9, 10). These
arlier studies established that a close antigenic rela-
ionship existed between TBEV and LGT. Also, the se-
uences of the structural proteins preM and E of theselaviviruses are 85–88% homologous (15). Thus, we were
ot surprised to observe that the level of neutralizing
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30 RAPID COMMUNICATIONantibodies measured against LGT TP21 virus showed a
correlation with protective immunity to TBEV. In this ex-
periment the LGT virus-specific immune response of
mice was measured by determining the titer of serum
LGT TP21 neutralizing antibodies induced by the chi-
meric vaccine candidate or its parental LGT virus. Indi-
vidual serum samples were analyzed by a 50% focus
reduction neutralization test (16, 17) using TP21 virus
(Table 4). Mice inoculated once with 102 PFU of TP21,
P21(656), or E5 virus or twice with 105 PFU of the
T
Intraperitoneal (ip) Immunization of Inbred Mice wit
against Subsequent ip Challenge wi
ip immunization
No. of inoculation(s)
(interval in days
between inoculations)
Mouse
strain
D
ch
600 PFU of
TP21/DEN4(vac)
chimera 1 BALB/c
CBA
2 (29) BALB/c
CBA
2 (26) BALB/c
3 (29, 39) BALB/c
4 (26, 66, 35) BALB/c
Tissue culture
medium BALB/c
CBA
T
Intraperitoneal (ip) Immunization of Swiss M
against Subsequent ip Challenge
ip immunization
Virus
Dose
(PFU)
No. of inoculations
(interval in days
between inoculations)
TP21 102 1
TP21/DEN4(vac) 105 1
2 (22)
E5 102 1
E5/DEN4(vac) 105 1
2 (22)
TP21-656b 102 1
EN4 105 1
issue culture
medium —
a Neutralizing antibodies in mouse serum collected 40 days after fir
sing TP21 virus.
b Mutant of cDNA-derived LGT strain TP21 (8).TP21/DEN4(vac) chimera developed a high level of neu-
tralizing antibodies against LGT TP21. In contrast, mice
inoculated ip with 105 PFU of DEN4 failed to develop
P21 neutralizing antibodies. Also, mice immunized with
ither chimeric virus once or E5/DEN4(vac) chimera
wice developed a moderate level of TP21 serum neu-
ralizing antibodies, which was lower then observed pre-
iously (6), when the mosquito cell culture-derived chi-
eric viruses were used for immunization of outbred
wiss mice.
Dose of Langat TP21/DEN4(vac) Chimera Protects
ly Virulent TBEV Strain Absettarov
ip challenge with 320 PFU of TBEV on indicated day
No. of
mice
No. that survived
(%)
Average survival time
of mice that died (days)
10 2 (20) 9.8
10 6 (60) 11.2
10 4 (40) 9.7
9 9 (100)
10 6 (60) 12.5
10 8 (80) 16
5 5 (100)
10 0 (0) 8.1
10 0
10 0
10 0
9 0 10.2
10 0
ith Langat (LGT)/DEN4 Chimeras Protects
ighly Virulent TBEV Strain Sofjin
-neutralizing
ody titera
ciprocal
etric mean)
ip challenge with 100 LD50 of TBEV on day 46
No.
mice
No. that
survived
(%)
Average survival
time of mice that
died (days)
1676 5 5 (100)
54 9 2 (22) 10.7
452 6 6 (100)
489 10 10 (100)
56 8 1 (12) 12.9
96 6 4 (67) 11.0
831 10 9 (90) 10.0
,20 8 0 (0) 10.6
,20 19 0 (0) 10.7
nization were measured by a 50% focus reduction neutralization testABLE 3
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26
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131RAPID COMMUNICATIONMice previously inoculated with a low dose of E5 or TP21
were fully protected against subsequent TBEV challenge,
whereas mice previously inoculated with DEN4 as well as
nonimmunized mice were not protected at all. This indi-
cates that protection was due to a broad LGT immune
response. Even a very low dose of live LGT virus (including
the cDNA-derived TP21 virus) was highly effective in pre-
venting disease caused by the antigenically related TBEV.
Mice also became resistant to subsequent lethal challenge
with the Far Eastern subtype strain of TBEV after immuni-
zation with the chimeric viruses. The TP21/DEN4(vac) ap-
peared to be more immunogenic than E5/DEN4(vac) be-
cause mice inoculated with two doses of the former were
fully protected against TBEV challenge. In contrast, only
67% of mice inoculated with two doses of E5/DEN4(vac)
chimera survived lethal challenge by TBEV. Clearly, the
parental LGT viruses were more immunogenic and protec-
tive than their DEN4 chimeras. However, it was possible to
achieve greater safety and equivalent protective efficacy
when the TP21/DEN4(vac) chimera was administered in a
two-dose regime.
Consistent with the close antigenic relationship of LGT
and TBEV, our studies with chimeric virus vaccine can-
didates in mice have shown a high degree of cross-
protection between LGT and the TBEV European subtype
(strain Absettarov) or the TBEV Far Eastern subtype
(strain Sofjin). Thus, the LGT preM and E proteins of the
chimeras represent effective protective antigens able to
induce significant resistance to heterologous challenge
with highly virulent TBEV. The encouraging results ob-
tained from analysis of the safety, immunogenicity, and
protective efficacy of the LGT/DEN4 chimeric candidate
vaccine strains in mice constitute a basis for expanding
our evaluation of the vaccine candidate to nonhuman
primates. As a consequence, dose escalation and immu-
nogenicity studies are underway in monkeys.
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